论文信息 - Symptomatic melanoma CNS metastases in the TRICOTEL study. - 字舞流文

Symptomatic melanoma CNS metastases in the TRICOTEL study.

A. Schmitt | J. Larkin

[1] P. Ascierto,et al. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. , 2022, The Lancet. Oncology.

[2] M. Atkins,et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. , 2021, The Lancet. Oncology.

[3] H. Tawbi,et al. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD) , 2019, Journal of Neuro-Oncology.

[4] Ying Zhang,et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. , 2017, The Lancet. Oncology.